How many drugs treat M lymphoplasmacytic?

Drug Landscape tracks 2 marketed treatments for M lymphoplasmacytic (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/m-lymphoplasmacytic.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

M lymphoplasmacytic — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

M lymphoplasmacytic (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating M lymphoplasmacytic, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	Line of therapy	First approval
Imbruvica	ibrutinib	AbbVie	Kinase Inhibitor [EPC]	Tyrosine-protein kinase Blk		2013-01-01
Imbruvica	Imbruvica	Rabin Medical Center		Nuclear receptor subfamily 4 group A member 3, Platelet glycoprotein VI, Serine/threonine-protein kinase LATS1

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

AbbVie · 1 drug in M lymphoplasmacytic
Rabin Medical Center · 1 drug in M lymphoplasmacytic

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in M lymphoplasmacytic:

Cite this brief

Drug Landscape (2026). M lymphoplasmacytic — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/m-lymphoplasmacytic. Accessed 2026-06-10.

M lymphoplasmacytic full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing